Why the study?
The study was conducted to explore the associations between glucocorticoid use and clinical outcomes in patients with severe pneumonia.
Does glucocorticoid use improve clinical outcomes and mortality in patients with severe pneumonia?
Does glucocorticoid use improve clinical outcomes and mortality in patients with severe pneumonia?
In patients with severe pneumonia, the use of glucocorticoids is associated with increased mortality, need for mechanical ventilation, and incidence of nosocomial infections.
Glucocorticoid use was associated with higher mortality in severe pneumonia; leaves open whether RCTs would confirm harm.
Objective. To explore the associations between glucocorticoid use and the clinical outcome of patients with severe pneumonia. Methods. Medical databases including PubMed, EMBASE, and ScienceDirect were searched for relevant literature. Two independent researchers extracted the primary endpoint from the included literature. The Cochrane <a:math xmlns:a="http://www.w3.org/1998/Math/MathML" id="M1"> <a:mi>Q</a:mi> </a:math> test and <c:math xmlns:c="http://www.w3.org/1998/Math/MathML" id="M2"> <c:msup> <c:mrow> <c:mi>I</c:mi> </c:mrow> <c:mrow> <c:mn>2</c:mn> </c:mrow> </c:msup> </c:math> statistics were used to evaluate the interstudy heterogeneity. The combined risk estimates were calculated by random effect model, and the source of heterogeneity was evaluated by subgroup analysis. Funnel plot and Egger’s test were used to assess publication bias. <e:math xmlns:e="http://www.w3.org/1998/Math/MathML" id="M3"> <e:mi>P</e:mi> <e:mo><</e:mo> <e:mn>0.05</e:mn> </e:math> denoted statistical significance. Results. A total of 12 literature, including 8171 patients with 1083 deaths, were included in this study for meta-analysis. The use of glucocorticoids significantly increased the mortality ( <g:math xmlns:g="http://www.w3.org/1998/Math/MathML" id="M4"> <g:mtext>RR</g:mtext> <g:mo>=</g:mo> <g:mn>1.44</g:mn> </g:math> , 95% CI: 1.13, 1.84, <i:math xmlns:i="http://www.w3.org/1998/Math/MathML" id="M5"> <i:mi>P</i:mi> <i:mo><</i:mo> <i:mn>0.001</i:mn> </i:math> ), the risk of requiring mechanical ventilation ( <k:math xmlns:k="http://www.w3.org/1998/Math/MathML" id="M6"> <k:mtext>RR</k:mtext> <k:mo>=</k:mo> <k:mn>1.62</k:mn> </k:math> , 95% CI: 1.30, 2.02, <m:math xmlns:m="http://www.w3.org/1998/Math/MathML" id="M7"> <m:mi>P</m:mi> <m:mo><</m:mo> <m:mn>0.001</m:mn> </m:math> ), and the incidence of nosocomial infection ( <o:math xmlns:o="http://www.w3.org/1998/Math/MathML" id="M8"> <o:mtext>RR</o:mtext> <o:mo>=</o:mo> <o:mn>1.36</o:mn> </o:math> , 95% CI: 1.01, 1.82, <q:math xmlns:q="http://www.w3.org/1998/Math/MathML" id="M9"> <q:mi>P</q:mi> <q:mo>=</q:mo> <q:mn>0.04</q:mn> </q:math> ) in patients with severe pneumonia as compared with the control group. In addition, the use of glucocorticoids did not seem to be associated with length of treatment in the intensive care unit ( <s:math xmlns:s="http://www.w3.org/1998/Math/MathML" id="M10"> <s:mtext>mean</s:mtext> <s:mtext> </s:mtext> <s:mtext>difference</s:mtext> <s:mo>=</s:mo> <s:mn>1.47</s:mn> </s:math> , 95% CI: -1.04, 3.96, <u:math xmlns:u="http://www.w3.org/1998/Math/MathML" id="M11"> <u:mi>P</u:mi> <u:mo>=</u:mo> <u:mn>0.25</u:mn> </u:math> ) and the length of hospital stay ( <w:math xmlns:w="http://www.w3.org/1998/Math/MathML" id="M12"> <w:mtext>mean</w:mtext> <w:mtext> </w:mtext> <w:mtext>difference</w:mtext> <w:mo>=</w:mo> <w:mn>0.55</w:mn> </w:math> , 95% CI: -3.90, 4.99, <y:math xmlns:y="http://www.w3.org/1998/Math/MathML" id="M13"> <y:mi>P</y:mi> <y:mo>=</y:mo> <y:mn>0.81</y:mn> </y:math> ). Conclusion. The use of glucocorticoids may increase the mortality, the incidence of hospital-acquired pneumonia, and the need for mechanical ventilation in patients with severe pneumonia.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: